Targeted therapies in cancer: where are we going?

References

[1] Gutierrez ME,Giaccone G.Next generation oncology drug development: opportunities and challenges..Nat Rev Clin Oncol2009;6:259-65

[2] Park SR,Doroshow JH.Safety and feasibility of targeted agent combinations in solid tumours..Nat Rev Clin Oncol2013;10:154-68

[3] Rolfo C,Santarpia M,Giovannetti E,Pauwels P.Immunotherapy in NSCLC: a promising and revolutionary weapon..Adv Exp Med Biol2017;995:97-125

[4] Hochhaus A,Guilhot F,Branford S,Baccarani M,Cervantes F,Ortmann CE,Kantarjian H,Druker BJ.Long-term outcomes of imatinib treatment for chronic myeloid leukemia..N Engl J Med2017;376:917-27 PMCID:PMC5901965

[5] Van Der Steen N,Deschoolmeester V,Lardon F,Germonpré P,Peters GJ.Better to be alone than in bad company: the antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer..World J Clin Oncol2016;7:425-32 PMCID:PMC5143436

[6] Codacci-Pisanelli G,Mini E.Three cheers for targeted therapy in non-small cell lung cancer....When we hit the target! J Chemother2011;23:245-6

[7] Kwak EL,Camidge DR,Solomon B,Ou SH,Jänne PA,Varella-Garcia M,Lynch TJ,Stubbs H,Sequist LV,Gandhi L,Wei GC,Ratain MJ,Christensen JG,Wilner K,Shapiro GI,Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer..N Engl J Med2010;363:1693-703 PMCID:PMC3014291

[8] Amirouchene-Angelozzi N,Bardelli A.Tumor evolution as a therapeutic target..Cancer Discov2017;doi: 10.1158/2159-8290.CD-17-0343.

[9] Herbst RS,Schiller JH,Miller V,Scagliotti G,Oliff I,Wolf MK,Averbuch SD,Grous J,Johnson DH.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2..J Clin Oncol2004;22:785-94

[10] Giaccone G,Manegold C,Rosell R,Natale RB,Von Pawel J,Gatzemeier U,Ochs JS,Wolf MK,Fandi A.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1..J Clin Oncol2004;22:777-84

[11] Van Der Steen N,Rolfo C,Peters GJ.New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?.Onco Targets Ther2016;9:6065-74 PMCID:PMC5063481

[12] Knight LA,Whitehouse P,Sharma S,Johnson P.The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours..BMC Cancer2004;4:83 PMCID:PMC535559

[13] Van Schaeybroeck S,Kelly D,Galligan L,Johnston P.Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy..Clin Cancer Res2005;11:7480-9

[14] Bianco C,Ciardiello F,Nannizzi S,Troiani T,Eckhardt G,Ricciardi S,Raben D,Danesi R.Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer..Clin Cancer Res2006;12:7099-107

[15] Li T,Goldman ID.Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells..Clin Cancer Res2007;13:3413-22

[16] Xu JM,Severino M,Colucci G.Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin..Biochem Pharmacol2003;66:551-63

[17] Magné N,Tiffon C,Dubreuil A,Formento JL,Ciccolini J,Milano G.Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil..Br J Cancer2003;89:585-92 PMCID:PMC2394392

[18] Greco WR,Parsons JC.The search for synergy: a critical review from a response surface perspective..Pharmacol Rev1995;47:331-85

[19] Chou TC.Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies..Pharmacol Rev2006;58:621-81